Last mentioned: Mar 21, 2026
Anticipated PDUFA
Expected deadline for the FDA's final approval decision.
Court Ruling
Judge Brian Murphy issues a stay, halting the implementation of the vaccine overhaul.
Legal Challenge
The AAP and ACP file suit in Massachusetts federal court to block the changes.
Settlement Reached
Moderna agrees to pay up to $2.25 billion to resolve all outstanding claims.
FDA U-Turn
FDA agrees to review the application after resolving the public dispute.
Regulatory Reversal
FDA agrees to review the application after Moderna addresses concerns.
Political Controversy
Reports emerge that the vaccine chief overruled career scientists to block the shot.
Refusal to File
FDA issues a shocking rejection of the application, sparking a public dispute.
Refusal to File
FDA issues an RTF citing deficiencies in the initial application.
BLA Submission
Moderna submits Biologics License Application for mRNA-1010.
Initial BLA Submission
Moderna submits its Biologics License Application for mRNA-1010.
ACIP Restructuring
HHS replaces existing ACIP members with figures aligned with the administration's views.
HHS Policy Shift
Secretary RFK Jr. issues a memo reducing universal vaccine recommendations.
Claims Construction
Court rulings on patent definitions provide momentum for the plaintiffs.
Lawsuit Filed
Arbutus and Genevant sue Moderna for patent infringement in Delaware federal court.
Vaccine Launch
Moderna receives EUA for Spikevax, utilizing LNP technology for delivery.
A Massachusetts federal judge has blocked the Trump administration's attempts to dismantle the standard U.S. vaccine schedule. The ruling halts Robert F. Kennedy Jr.’s efforts to reduce recommended pediatric immunizations, citing a failure to follow established scientific and procedural laws.
Preliminary reports from US health officials indicate that this season's influenza vaccines provided lower-than-expected protection against circulating strains. The findings underscore the persistent challenge of viral mismatch and are expected to accelerate the industry's shift toward next-generation mRNA and recombinant vaccine technologies.
Wholesale egg prices have dropped significantly as the poultry industry recovers from devastating H5N1 outbreaks. However, the biotech sector remains on high alert as researchers and regulators weigh the long-term necessity of mass poultry vaccination and human pandemic preparedness.
Moderna (MRNA) shares rose significantly on March 4, 2026, as part of a broader market rally that lifted high-growth technology and clean energy stocks. The move highlights a renewed investor appetite for innovative platforms, signaling a potential recovery for the biotech sector following a period of macro-induced volatility.
Moderna has reached a landmark $2.25 billion settlement with Roivant Sciences and Arbutus Biopharma to resolve long-standing patent disputes over lipid nanoparticle technology used in its COVID-19 vaccine. The agreement provides a massive capital infusion for Roivant while removing a significant legal overhang for Moderna's future mRNA pipeline.
The FDA has rescinded its initial refusal to file Moderna’s Biologics License Application for its seasonal flu vaccine, mRNA-1010. This rare regulatory pivot clears the path for a formal review of the first mRNA-based influenza shot, a critical milestone for Moderna’s post-pandemic growth strategy.
Moderna has confirmed that the FDA will officially review its mRNA-based influenza vaccine following a highly publicized regulatory standoff. The reversal comes after reports that the Trump administration's vaccine leadership initially overruled career scientists to block the application.
This page surfaces every story mentioning Moderna across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Moderna was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |